Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) Director Nathaniel E. David sold 1,540 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $37.37, for a total transaction of $57,549.80. Following the sale, the director now directly owns 489,627 shares in the company, valued at approximately $18,297,361. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 1.53% during mid-day trading on Thursday, hitting $36.16. The stock had a trading volume of 99,886 shares. KYTHERA Biopharmaceuticals has a 52 week low of $26.90 and a 52 week high of $56.36. The stock has a 50-day moving average of $35.0 and a 200-day moving average of $37.51. The company’s market cap is $819.8 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last announced its earnings results on Thursday, August 7th. The company reported ($0.86) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.83) by $0.03. Analysts expect that KYTHERA Biopharmaceuticals will post $-3.34 EPS for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Receive News & Ratings for KYTHERA Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KYTHERA Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.